ARIAD Pharmaceuticals (ARIA) : The value of composite uptick trades was $0.27 million, whereas, the value of composite downtick trades was $0.77 million. The uptick to downtick ratio stood at 0.34 with a negative money flow of ($0.51) Million during Fridays trading session. The block trades money flow was negative ($0.38 million). The transaction of the trades on downticks amounted to $0.38 million, which confirms investors selling on the strength of price. ARIAD Pharmaceuticals (ARIA) gained 1 cents at $7.99, an increase of 0.13% over the previous days close.
ARIAD Pharmaceuticals (ARIA) : Currently there are 5 street experts covering ARIAD Pharmaceuticals (ARIA) stock. The most bullish and bearish price target for the stock is $13 and $8 respectively for the short term. The average price target of all the analysts comes to $10.4. The estimated standard deviation from the target is $2.07.
ARIAD Pharmaceuticals (NASDAQ:ARIA): stock turned positive on Friday. Though the stock opened at $7.97, the bulls momentum made the stock top out at $8.24 level for the day. The stock recorded a low of $7.89 and closed the trading day at $8.11, in the green by 1.63%. The total traded volume for the day was 6,136,555. The stock had closed at $7.98 in the previous days trading.
In a related news, The Securities and Exchange Commission has divulged that Clackson Timothy P, officer (President, R&D, CSO) of Ariad Pharmaceuticals Inc, had unloaded 61,422 shares at an average price of $7.48 in a transaction dated on July 1, 2016. The total value of the transaction was worth $459,437.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).